Manufacturing transitions during an active Phase 2 trial are where gene therapy programs quietly collapse, so the fact that Pacira completed this one without a single day of enrollment delay in the ASCEND study is the real story here. The company has now dosed the first patient in Part B of ASCEND using product from a U.S.-based scalable commercial manufacturing process, the same process it intends to carry through registration and into commercialization. That alignment matters enormously: regulators expect clinical data generated with the intended commercial process, and threading that requirement into Phase 2 rather than scrambling to address it in Phase 3 removes one of the most common late-stage stumbling blocks in gene therapy development.
The mechanics of the ASCEND design deserve attention. Part A randomized 49 patients across Dose A (1.4 × 10¹⁰ genome copies) and Dose B (1.4 × 10¹¹ genome copies) against saline, with topline safety and efficacy data expected by year-end 2026. Part B will randomize roughly 90 additional patients using the new manufacturing process, expanding total enrollment to approximately 135 and generating the bridging dataset that regulators will need to accept process comparability. All participants carry Kellgren-Lawrence grades 2 through 4 and receive intra-articular methylprednisolone pretreatment to support tolerability and gene transfer. The primary endpoint runs through Week 52 on safety parameters, with pain and function secondaries measured at Weeks 38 and 52 via NRS, WOMAC, and KOOS. A five-year follow-up extends well past what most Phase 2 programs commit to, which signals that Pacira is treating durability as a core commercial argument, not an afterthought.
The underlying platform adds strategic texture. Pacira’s proprietary high-capacity adenovirus vector carries up to 30,000 base pairs of DNA, supports local administration, and is designed for potential redosing, characteristics that separate it from AAV-based approaches in a structural way. Phase 1 data reported through three years showed durable improvements in knee pain, stiffness, and function, and the program has earned both FDA RMAT designation and EMA ATMP designation, the latter granted in May 2023. Osteoarthritis of the knee affects more than 15 million people in the United States alone, and the current standard leans heavily on corticosteroids and physical management rather than disease-modifying intervention.
The number to watch arriving at year-end is the Part A safety profile at Week 52. If treatment-emergent adverse events and immunogenicity signals stay clean at the higher dose, Part B enrollment momentum becomes a straight line to a registrational design conversation, and the manufacturing bridge Pacira just completed means that conversation can start without a process detour.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
